1. Australia Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Compumedics Limited

Compumedics Limited

CMP.AX
Compumedics LimitedAU flagAustralian Securities Exchange
0.22
AUD
-0.03
- -
43.95MMarket Cap
Compumedics Limited
CMP.AX
(Australian Securities Exchange)

Recent

price

0.22

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.2
0.19
0.17
0.16
0.17
0.2
0.22
0.19
0.21
0.24
0.2
0.21
0.22
0.24
1
- -
Revenue per Share
- -
- -
-0.02
-0.01
0.01
0.01
0.02
0.01
0.02
0.02
-0.03
0.01
0.01
-0.03
-0.01
- -
Basic EPS, GAAP
- -
-0.01
0.01
- -
- -
0.01
- -
- -
-0.01
-0.02
-0.02
-0.01
-0.02
-0.02
-0.06
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.08
0.08
0.06
0.05
0.06
0.07
0.09
0.12
0.13
0.16
0.12
0.14
0.14
0.1
0.37
- -
Book Value per Share
0.05
0.05
0.03
0.03
0.03
0.05
0.07
0.1
0.11
0.12
0.11
0.11
0.1
0.07
0.16
- -
Tangible Book Value per Share
161
162
162
167
167
164
169
177
177
173
177
166
170
177
50
182
Basic Weighted Avg Shares
32
31
28
27
29
33
38
34
37
42
35
36
38
42
50
- -
Sales/Revenue/Turnover
1.19
-4.19
-10.65
-10.53
-8.46
-2.34
2.26
-1.87
6.96
10.94
-6.7
-2.96
-2.85
-10.72
-4.79
- -
Operating Margin (%)
- -
1
1
1
1
2
2
1
- -
- -
2
1
1
1
2
- -
Depreciation Expense
- -
- -
-3
-1
1
2
3
1
3
4
-6
1
1
-6
- -
- -
Net Income, GAAP
- -
- -
- -
- -
6.48
2.04
- -
- -
20.16
21.05
- -
- -
20.08
- -
153.75
- -
Effective Tax Rate (%)
1.39
0.26
-10.13
-5.48
3.13
5.88
8.72
3.79
7.52
9.68
-16.65
2.79
3.59
-14.44
-0.68
- -
Profit Margin (%)
13
12
10
10
12
14
11
16
19
20
26
29
28
21
5
- -
Working Capital
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
- -
2
1
- -
LT Debt
11
12
8
8
8
11
15
20
23
27
22
22
24
19
18
- -
Total Equity
2.91
- -
- -
- -
-22.07
-6.59
- -
- -
8.96
13.26
- -
- -
-2.65
- -
4.02
- -
Return on Invested Capital (%)
6.75
- -
- -
- -
12.78
20.46
- -
- -
12.56
15.45
- -
- -
5.69
- -
-2.71
- -
Return on Capital (%)
3.49
0.62
-24.38
-15.56
9.67
18.17
24.18
7.24
12.55
15.7
-23.72
4.51
5.82
-29.26
-1.87
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
42
2024
- -
- -
- -
- -
50
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.03
2024
- -
- -
- -
- -
-0.01
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Cyclopharm Limited (CYC.AX)
Holdco Nuvo Group D.G Ltd. Warrants (NUVOW)
Manhattan Scientifics, Inc. (MHTX)
BICO Group AB (publ) (BCCOY)
ResMed Inc. (RMD.AX)
STRATA Skin Sciences, Inc. (SSKN)
Business
Compumedics Limited Compumedics Limited engages in the development, manufacture, and commercialization of diagnostic technologies for sleep disorders, brain function including neurological research, and ultrasonic blood-flow monitoring applications. The company offers a comprehensive range of products including sleep diagnostics systems such as Somfit, Somté PSG, Grael PSG, Grael 4K PSG, Falcon PSG, Falcon HST, Siesta 802, and Okti; neurology solutions encompassing Profusion EEG software, Profusion neXus 360 web-based patient data management, CURRY signal processing, Nuevo LTM EEG, Orion LifeSpan MEG magnetoencephalography systems, and quick-cap EEG electrode arrays; ultrasonic Doppler diagnostics via its DWL brand; software platforms for scalable operations; and consumables, supplies, and accessories for diagnostic and research use. Compumedics Limited serves sleep clinics, neurology departments, hospitals, pharmaceutical clinical trials, and research institutions targeting patients with sleep apnea, neurological disorders, epilepsy, and vascular conditions. The company operates geographically across the Americas through its US-based Neuroscan subsidiary in Charlotte, North Carolina; Australia and Asia Pacific with significant presence in China, South Korea, and other regions; and Europe and the Middle East via its Germany-based DWL Elektronische GmbH operations in Singen, Dresden, Freiberg, and France in Strasbourg; with global headquarters in Abbotsford, Victoria, Australia. Founded in 1987 by Executive Chairman Dr. David Burton, who designed Australia's first fully computerized sleep clinic, the company listed on the Australian Securities Exchange in 2000 as ASX: CMP and maintains a subsidiary structure without a listed parent. Recent developments include signing two four-year distribution agreements in China in July 2025 valued at A$24.4 million with long-term partners, featuring minimum 10% annual growth commitments for sleep diagnostics in Northern China and sleep/neurology in Eastern China; achieving record FY2025 orders of A$63.4 million, revenues of A$51.0 million, and EBITDA of A$2.9 million driven by SaaS growth; securing a fifth MEG sale of A$4.9 million in November 2025 fueled by China demand; FDA clearance for single-use SomfitD expanding the US market; multiple Somfit sales to pharmaceutical contract research organizations including a US$1 million deal; board renewal with the appointment of Christopher R. Barys, former Johnson & Johnson executive, in September 2025; and ongoing magnetoencephalography installations such as at Tianjin Normal University in China.